References
- Narsimha S, Kumar NS, Battula KS, Nagavelli VR, Hussain SKA, Rao MS. Indole-2-carboxylic acid derived mono and bis 1,4-disubstituted 1,2,3-triazoles: synthesis, characterization and evaluation of anticancer, antibacterial, and DNA-cleavage activities. Bioorg Med Chem Lett. 2016;26(6):1639–1644. doi:10.1016/j.bmcl.2016.01.05526873415
- Eckford PDW, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chemical Reviews. 2009;109(7):2989–3011. doi:10.1021/cr900022619583429
- Singh MS, Tammam SN, Shetab BMA, Lamprecht A. MDR in cancer: addressing the underlying cellular alterations with the use of nanocarriers. Pharmacol Res. 2017;126:2–30. doi:10.1016/j.phrs.2017.07.02328760489
- Kroto HW, Heath JR, O’Brien SC, Curl RF, Smalley RE. C60:buckminsterfullerene. Nature. 1985;318:162–163. doi:10.1038/318162a0
- Bosi S, Da Ros T, Spalluto G, Prato M. Fullerene derivatives: an attractive tool for biological applications. Eur J Med Chem. 2003;38(11–12):913–923.14642323
- Tokuyama H, Yamago S, Nakamura E, Shiraki T, Sugiura Y. Photoinduced biochemical activity of fullerene carboxylic acid. J Am Chem Soc. 1993;115(17):7918–7919. doi:10.1021/ja00070a064
- Friedman SH, Ganapathi PS, Rubin Y, Kenyon GL. Optimizing the binding of fullerene inhibitors of the HIV-1 protease through predicted increases in hydrophobic desolvation. J Med Chem. 1998;41(13):2424–2429. doi:10.1021/jm970689r9632374
- Kataoka H, Ohe T, Takahashi K, Nakamura S, Mashino T. Novel fullerene derivatives as dual inhibitors of Hepatitis C virus NS5B polymerase and NS3/4A protease. Bioorg Med Chem Lett. 2016;26(19):4565–4567. doi:10.1016/j.bmcl.2016.08.08627597249
- Mashino T, Shimotohno K, Ikegami N, et al. Human immunodeficiency virus-reverse transcriptase inhibition and hepatitis C virus RNA-dependent RNA polymerase inhibition activities of fullerene derivatives. Bioorg Med Chem Lett. 2005;15(4):1107–1109. doi:10.1016/j.bmcl.2004.12.03015686922
- Nakamura S, Mashino T. Water-soluble fullerene derivatives for drug discovery. J Nippon Med Sch. 2012;79(4):248–254.22976602
- Yasuno T, Ohe T, Takahashi K, Nakamura S, Mashino T. The human immunodeficiency virus-reverse transcriptase inhibition activity of novel pyridine/pyridinium-type fullerene derivatives. Bioorg Med Chem Lett. 2015;25(16):3226–3229. doi:10.1016/j.bmcl.2015.05.08626081290
- Bosi S, Da Ros T, Castellano S, Banfi E, Prato M. Antimycobacterial activity of ionic fullerene derivatives. Bioorg Med Chem Lett. 2000;10(10):1043–1045.10843212
- Tsao N, Luh TY, Chou C, et al. In vitro action of carboxyfullerene. J Antimicrob Chemother. 2002;49(4):641–649. doi:10.1093/jac/49.4.64111909838
- Mashino T, Nishikawa D, Takahashi K, et al. Antibacterial and antiproliferative activity of cationic fullerene derivatives. Bioorg Med Chem Lett. 2003;13(24):4395–4397.14643333
- Nishizawa C, Hashimoto N, Yokoo S, et al. Pyrrolidinium-type fullerene derivatives-induced apoptosis by the generation of reactive oxygen species in HL-60 cells. Free Radical Research. 2009;43(12):1240–1247. doi:10.3109/1381478090326076419905986
- Yamori T. Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics. Cancer Chemother Pharmacol. 2003;52 Supp(1):S74–S79. doi:10.1007/s00280-003-0649-112819939
- Filippone S, Maroto EE, Martín-Domenech Á, Suarez M, Martín N. Anefficient approach to chiral fullerene derivatives by catalytic enantioselective 1,3-dipolar cycloadditions. Nat Chem. 2009;1:578–582.21500388